Nvidia, AMD to pay 15% of China chip sales revenue to US govt- FT
Director Sheena Jonathan of Natera, Inc. (NASDAQ:NTRA) sold 3,070 shares of common stock on July 16, 2025, at prices ranging from $149.59 to $150.52, netting approximately $460,387. The sale occurred as the stock traded near $139, down about 13% over the past week. According to InvestingPro data, Natera commands a market capitalization of $18.9 billion, with its Financial Health Score rated as "GOOD."
The transaction was executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 11, 2024. Following the sale, Jonathan directly owns 245,704 shares of Natera common stock. The company’s stock has shown significant volatility, with a beta of 1.73, though it maintains strong liquidity with a current ratio of 3.87.
Additionally, Jonathan indirectly owns 35,782 shares through the Caraluna 1 Trust and another 35,782 shares through the Caraluna 2 Trust. Jonathan disclaims beneficial ownership of these shares held by the trusts. Despite recent price volatility, InvestingPro analysis reveals 12 additional key insights about Natera’s performance and prospects, available in the comprehensive Pro Research Report.
In other recent news, Natera has reported significant developments that could impact investor perspectives. The company announced its Q1 2025 earnings, revealing a revenue of $522 million, which marks a 37% increase year-over-year, surpassing analysts’ expectations. This strong performance led to a revised full-year revenue guidance of $1.94 to $2.02 billion. Meanwhile, Medicare has expanded coverage for Natera’s Signatera MRD assay to include a wider range of cancers, enhancing accessibility for patients. Analysts at RBC Capital Markets have maintained an Outperform rating on Natera, citing the company’s robust quarterly performance and raised guidance as indicators of continued growth potential.
Additionally, TD Cowen adjusted its price target for Natera shares to $200, while maintaining a Buy rating, emphasizing the company’s impressive 13% higher-than-expected sales. Leerink Partners also reiterated an Outperform rating, highlighting the new Medicare coverage for Natera’s WGS Signatera assay as a positive development. The recent Medicare decision covers multiple cancer types, which could lead to increased usage and reimbursement opportunities for the company. These updates reflect a period of substantial growth and strategic advancements for Natera, positioning it favorably in the market.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.